
Joseph Michael Scandura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6953044/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Excess mortality in younger patients with myeloproliferative neoplasms. Leukemia and Lymphoma, 2023, 64, 725-729.	1.3	5
2	Normal life expectancy for polycythemia vera (PV)Âpatients is possible. Leukemia, 2022, 36, 569-572.	7.2	16
3	Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer, 2022, 128, 2420-2432.	4.1	24
4	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. Cancer Discovery, 2022, 12, 2120-2139.	9.4	14
5	Hematopoietic fitness of <i>JAK2V617F</i> myeloproliferative neoplasms is linked to clinical outcome. Blood Advances, 2022, 6, 5477-5481.	5.2	4
6	Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms. European Journal of Haematology, 2021, 106, 250-259.	2.2	7
7	Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia, 2021, 35, 2592-2601.	7.2	52
8	Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage. Communications Biology, 2021, 4, 785.	4.4	3
9	Reversal of emphysema by restoration of pulmonary endothelial cells. Journal of Experimental Medicine, 2021, 218, .	8.5	37
10	Diffuse Large B Cell Pdtx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents. Blood, 2021, 138, 2406-2406.	1.4	1
11	Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for <i>JAK2 V617F</i> Myeloproliferative Neoplasms (MPNs). Blood, 2021, 138, 627-627.	1.4	1
12	Normal Life Expectancy for Polycythemia Vera Patients Is Possible. Blood, 2021, 138, 2575-2575.	1.4	1
13	Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial. Blood, 2021, 138, 141-141.	1.4	16
14	Extracting and classifying diagnosis dates from clinical notes: A case study. Journal of Biomedical Informatics, 2020, 110, 103569.	4.3	9
15	Hepcidin Is Essential for Alveolar Macrophage Function and Is Disrupted by Smoke in a Murine Chronic Obstructive Pulmonary Disease Model. Journal of Immunology, 2020, 205, 2489-2498.	0.8	13
16	Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. Blood, 2020, 135, 1062-1066.	1.4	19
17	Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression. Haematologica, 2020, 105, e221-e224.	3.5	8
18	Megakaryocyte TGFβ1 partitions erythropoiesis into immature progenitor/stem cells and maturing precursors. Blood, 2020, 136, 1044-1054.	1.4	11

#	Article	IF	CITATIONS
19	Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival. Blood, 2020, 136, 31-32.	1.4	4
20	Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature, 2019, 571, 355-360.	27.8	206
21	Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm–Associated Pulmonary Hypertension. Journal of the American Society of Echocardiography, 2019, 32, 1574-1585.	2.8	12
22	Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. Biology of Blood and Marrow Transplantation, 2019, 25, 466-473.	2.0	4
23	Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival. Blood, 2019, 134, 2942-2942.	1.4	1
24	Recombinant Interferon-α Reduces Thrombotic Events in Patients with Polycythemia Vera. Blood, 2019, 134, 1664-1664.	1.4	1
25	Low-Dose Epo after Tgfî² Blockade Triggers Robust Erythropoiesis and Increased RBC Production. Blood, 2019, 134, 2217-2217.	1.4	0
26	CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. Leukemia and Lymphoma, 2018, 59, 821-828.	1.3	11
27	Lessons Learned in the Development of a Computable Phenotype for Response in Myeloproliferative Neoplasms. , 2018, 2018, 328-331.		3
28	Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia. Haematologica, 2018, 103, 1308-1316.	3.5	34
29	Myeloproliferative Neoplasm (MPN) Driver Mutations Are Enriched during Hematopoietic Stem Cell Differentiation in Patterns That Correlate with Clinical Phenotype and Treatment Response. Blood, 2018, 132, 4317-4317.	1.4	2
30	Development of an Automated Tool for Assessing Response in Patients with Polycythemia Vera. Blood, 2018, 132, 5462-5462.	1.4	1
31	Ruxolitinib Can Lead to Weight Gain in Patients with Myeloproliferative Neoplasms By Uncoupling Feeding from Central Leptin Signaling Via JAK2/STAT3. Blood, 2018, 132, 4284-4284.	1.4	1
32	High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations. Blood, 2018, 132, 541-541.	1.4	1
33	A Clinical Review of the Co-Occurrence of Myeloproliferative and Lymphoproliferative Neoplasms. Blood, 2018, 132, 4285-4285.	1.4	0
34	Initial Therapy of Polycythemia Vera (PV) with Interferon Alfa (rIFNa) Compared to Hydroxyurea (HU) or Phlebotomy Only (PHL-O) Is Associated with a Lower Risk of Secondary Myelofibrosis. Blood, 2018, 132, 4316-4316.	1.4	0
35	Sox17 drives functional engraftment of endothelium converted from non-vascular cells. Nature Communications, 2017, 8, 13963.	12.8	18
36	Conversion of adult endothelium to immunocompetent haematopoietic stem cells. Nature, 2017, 545, 439-445.	27.8	191

#	Article	IF	CITATIONS
37	Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem Cells. Cancer Cell, 2017, 31, 110-126.	16.8	108
38	Conversion of adult endothelium into immune-competent haematopoietic stem cells. Experimental Hematology, 2017, 53, S82.	0.4	1
39	Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response. Clinical Cancer Research, 2017, 23, 2673-2680.	7.0	49
40	Abstract 4646: A novel truncated variant of the hematopoietic Hβ-1 tubulin isotype with implications for stem cell biology. , 2017, , .		0
41	Megakaryocytic TGFβ1 Partitions Hematopoiesis into Amplifying Stem and Progenitor Cells and Maturing Effector Cells. Blood, 2017, 130, 81-81.	1.4	0
42	KRAS and the Reality of Personalized Medicine in Non-Small Cell Lung Cancer. Molecular Medicine, 2016, 22, 380-387.	4.4	14
43	Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 297-303.	0.4	19
44	Step-wise reprogramming of endothelial cells into immune-competent hematopoietic stem cells. Experimental Hematology, 2016, 44, S48-S49.	0.4	0
45	Transplantation of Endothelial Cells to Mitigate Acute and Chronic Radiation Injury to Vital Organs. Radiation Research, 2016, 186, 196-202.	1.5	21
46	A Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S24.	0.4	0
47	Direct Conversion of Adult Endothelial Cells into Immunecompetent Long-Term Engraftable Clinically Scalable Hematopoietic Stem Cells: Pathway to Therapeutic Translation. Blood, 2016, 128, 372-372.	1.4	1
48	Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies. Blood, 2016, 128, 2816-2816.	1.4	0
49	Cutting the brakes on hematopoietic regeneration by blocking TGFÎ ² to limit chemotherapy-induced myelosuppression. Molecular and Cellular Oncology, 2015, 2, e978703.	0.7	5
50	An Alternative Retinoic Acid-responsive Stra6 Promoter Regulated in Response to Retinol Deficiency. Journal of Biological Chemistry, 2015, 290, 4356-4366.	3.4	23
51	A phase I trial of a pharmacodynamically-conceived decitabine/thioguanine combination in patients with advanced myeloid malignancies Journal of Clinical Oncology, 2015, 33, e18025-e18025.	1.6	0
52	Abstract 5096: ALIBI: a novel, truncated tubulin isotype in AML and stem cells. , 2015, , .		0
53	The Rad50 hook domain regulates DNA damage signaling and tumorigenesis. Genes and Development, 2014, 28, 451-462.	5.9	43
54	Angiocrine Factors Deployed by Tumor Vascular Niche Induce B Cell Lymphoma Invasiveness and Chemoresistance. Cancer Cell, 2014, 25, 350-365.	16.8	203

#	Article	IF	CITATIONS
55	Activation of the vascular niche supports leukemic progression and resistance to chemotherapy. Experimental Hematology, 2014, 42, 976-986.e3.	0.4	47
56	Reprogramming human endothelial cells to haematopoietic cells requires vascular induction. Nature, 2014, 511, 312-318.	27.8	211
57	Interleukin 2 Receptor-α (CD25) Expression Is Associated with Shortened Overall Survival and Resistance to Induction Therapy with Plerixafor and Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2014, 124, 1041-1041.	1.4	2
58	Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib. Blood, 2014, 124, 1811-1811.	1.4	3
59	Comprehensive Geriatric Assessment Does Not Predict Overall Survival in Older Patients with Acute Myeloid Leukemia (AML). Blood, 2014, 124, 3689-3689.	1.4	1
60	Direct Reprogramming of Amniotic Cells into Endothelial Cells. , 2014, , 67-85.		0
61	Phase I study of epigenetic priming using azacitidine prior to neoadjuvant chemotherapy in patients with resectable esophageal and gastric adenocarcinoma Journal of Clinical Oncology, 2014, 32, 4047-4047.	1.6	0
62	A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies. Blood, 2014, 124, 974-974.	1.4	0
63	RAR ^{ĵ3} is Essential for Retinoic Acid Induced Chromatin Remodeling and Transcriptional Activation in Embryonic Stem Cells. Journal of Cell Science, 2013, 126, 999-1008.	2.0	50
64	Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leukemia and Lymphoma, 2013, 54, 2003-2007.	1.3	137
65	Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nature Medicine, 2013, 19, 50-56.	30.7	174
66	TGFβ restores hematopoietic homeostasis after myelosuppressive chemotherapy. Journal of Experimental Medicine, 2013, 210, 623-639.	8.5	73
67	A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia. Biology of Blood and Marrow Transplantation, 2013, 19, 1040-1045.	2.0	17
68	Combining Decitabine With Plerixafor Yields a High Response Rate In Newly Diagnosed Older Patients With AML. Blood, 2013, 122, 621-621.	1.4	6
69	Imatinib resistance and microcytic erythrocytosis in a Kit ^{V558î";T669I/+} gatekeeper-mutant mouse model of gastrointestinal stromal tumor. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2276-83.	7.1	26
70	Development of a vascular niche platform for expansion of repopulating human cord blood stem and progenitor cells. Blood, 2012, 120, 1344-1347.	1.4	90
71	Are low-intensity induction strategies better for older patients with acute myeloid leukemia?. Leukemia Research, 2012, 36, 407-412.	0.8	8
72	TGFβ Restores Hematopoietic Homeostasis After Chemotherapy Blood, 2012, 120, 2344-2344.	1.4	0

Joseph Michael Scandura

#	Article	IF	CITATIONS
73	Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood, 2011, 118, 1472-1480.	1.4	116
74	Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas. Cancer Discovery, 2011, 1, 587-597.	9.4	108
75	Epigenomic Reorganization of the Clustered Hox Genes in Embryonic Stem Cells Induced by Retinoic Acid. Journal of Biological Chemistry, 2011, 286, 3250-3260.	3.4	86
76	DNA Methylation of the First Exon Is Tightly Linked to Transcriptional Silencing. PLoS ONE, 2011, 6, e14524.	2.5	503
77	Abstract 1113: TGF \hat{I}^2 pathway activation limits hematopoietic recovery from chemotherapy. , 2011, , .		0
78	A Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by a Reduced Intensity Conditioning Allogeneic Stem-Cell Transplantation for Patients with Refractory leukemia Blood, 2010, 116, 1334-1334.	1.4	1
79	Abstract 2548: P57Kip2 restrains the stress response of hematopoietic stem cells and its absence leads to chemotherapy resistance. , 2010, , .		Ο
80	Abstract 2196: Genome-wide analysis of DNA methylation patterns in formaldehyde-fixed paraffin-embedded (FFPE) human tumor specimens. , 2010, , .		0
81	CDKN1C Modulates the Stress-Reponse of Hematopoietic Stem Cells Rendering Hematopoiesis Resistant to Chemotherapeutics. Blood, 2010, 116, 3162-3162.	1.4	Ο
82	Decitabine-Based Salvage Therapy in Adults with Acute Myeloid Leukemia Blood, 2009, 114, 2063-2063.	1.4	3
83	Evaluation of Alternative, "Low-intensity―Induction Regimens in Elderly Adults with Acute Myeloid Leukemia (AML) Blood, 2009, 114, 2066-2066.	1.4	1
84	Genome-Wide Analysis of DNA Methylation Patterns Reveals Dynamic Epigenetic Regulation of the AML Genome After Decitabine Treatment Blood, 2009, 114, 591-591.	1.4	1
85	Epigenetic Priming with Decitabine Prior to Standard Induction Chemotherapy in Less-Than-Favorable Risk Acute Myelogenous Leukemia (AML) Blood, 2009, 114, 3079-3079.	1.4	0
86	Tumor promoting properties of the ETS protein MEF in ovarian cancer. Oncogene, 2007, 26, 4032-4037.	5.9	37
87	Advances in the molecular genetics of acute leukemia. Current Oncology Reports, 2005, 7, 323-332.	4.0	5
88	Transforming growth factor Î ² -induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15231-15236.	7.1	221
89	Structural integrity and expression of the <i>L3MBTL</i> gene in normal and malignant hematopoietic cells. Genes Chromosomes and Cancer, 2004, 41, 203-213.	2.8	37
90	The Human L(3)MBT Polycomb Group Protein Is a Transcriptional Repressor and Interacts Physically and Functionally with TEL (ETV6). Journal of Biological Chemistry, 2003, 278, 15412-15420.	3.4	102

#	Article	IF	CITATIONS
91	Transcription factor fusions in acute leukemia: variations on a theme. Oncogene, 2002, 21, 3422-3444.	5.9	97
92	Structural and Functional Characterization of Platelet Receptor-mediated Factor VIII Binding. Journal of Biological Chemistry, 2000, 275, 13071-13081.	3.4	50
93	The Mechanism by Which Heparin Promotes the Inhibition of Coagulation Factor XIa by Protease Nexin-2. Journal of Biological Chemistry, 1997, 272, 26139-26144.	3.4	19
94	Progress Curve Analysis of the Kinetics with Which Blood Coagulation Factor XIa Is Inhibited by Protease Nexin-2. Biochemistry, 1997, 36, 412-420.	2.5	45
95	Factor X Bound to the Surface of Activated Human Platelets Is Preferentially Activated by Platelet-Bound Factor IXa. Biochemistry, 1996, 35, 8903-8913.	2.5	37
96	A Binding Site Expressed on the Surface of Activated Human Platelets Is Shared by Factor X and Prothrombinâ€. Biochemistry, 1996, 35, 8890-8902.	2.5	59